Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. - Wikidata - wikimedia - TriplyDB

Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up.

Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up.

http://www.wikidata.org/entity/Q42653222

about

Antioxidants and other pharmacological treatments for Friedreich ataxia Expression of human frataxin is regulated by transcription factors SRF and TFAP2 Coenzyme Q and Its Role in the Dietary Therapy against Aging Transition metals and mitochondrial metabolism in the heart Treatment of CoQ(10) deficient fibroblasts with ubiquinone, CoQ analogs, and vitamin C: time- and compound-dependent effects Coenzyme Q10 and Neurological Diseases.Iron in chronic brain disorders: imaging and neurotherapeutic implications.Combined therapy with idebenone and deferiprone in patients with Friedreich's ataxia.Mammalian frataxin: an essential function for cellular viability through an interaction with a preformed ISCU/NFS1/ISD11 iron-sulfur assembly complex.Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases.Impaired cardiovascular function in primary biliary cirrhosis.Coenzyme q10 therapy Coenzyme q and the respiratory chain: coenzyme q pool and mitochondrial supercomplexes Friedreich ataxia: molecular mechanisms, redox considerations, and therapeutic opportunities.Small molecules affecting transcription in Friedreich ataxia Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism.Co-enzyme Q10 and idebenone use in Friedreich's ataxia.Current experience in testing mitochondrial nutrients in disorders featuring oxidative stress and mitochondrial dysfunction: rational design of chemoprevention trials.Stem cells from wildtype and Friedreich's ataxia mice present similar neuroprotective properties in dorsal root ganglia cells.Cardiomyopathy of Friedreich's ataxia: use of mouse models to understand human disease and guide therapeutic development.The Heart in Friedreich's Ataxia: Basic Findings and Clinical Implications.Selected biomarkers as predictive tools in testing efficacy of melatonin and coenzyme Q on propionic acid - induced neurotoxicity in rodent model of autism.Consensus paper: management of degenerative cerebellar disorders.Mesenchymal stem cells improve motor functions and decrease neurodegeneration in ataxic mice.Mitochondrial energetics and therapeutics.A TAT-frataxin fusion protein increases lifespan and cardiac function in a conditional Friedreich's ataxia mouse model Oral repeated-dose toxicity studies of coenzyme Q10 in beagle dogs.Cardiac torsion-strain relationships in fatigued primary biliary cirrhosis patients show accelerated aging: a pilot cross-sectional study.New prospects and strategies for drug target discovery in neurodegenerative disorders Mitochondrial Respiratory Defect Causes Dysfunctional Lactate Turnover via AMP-activated Protein Kinase Activation in Human-induced Pluripotent Stem Cell-derived Hepatocytes.Redox processes in neurodegenerative disease involving reactive oxygen species Human coenzyme Q10 deficiency Drug development for rare mitochondrial disorders Liver disease in mitochondrial disorders.Childhood ataxia: clinical features, pathogenesis, key unanswered questions, and future directions.Coenzyme Q10 effects in neurodegenerative disease.Vitamin E is essential for Purkinje neuron integrity.Bioenergetic medicine.Understanding the molecular mechanisms of Friedreich's ataxia to develop therapeutic approaches.Current and emerging treatment options in the management of Friedreich ataxia.

P2860

Q24240370-B52E18F3-F78C-418B-9D94-427AAE7DB283 Q24298228-E185027A-08EB-48A5-915E-2CD144F8ED11 Q26753050-A52F87B5-21FD-492D-9006-5A9EA13F5B47 Q26999334-1D873CBF-294D-4455-898F-D29460A30002 Q28474996-63A748AB-A2B4-4BAD-9E30-CCB4A845AA4D Q30440307-DD1036BE-E7D8-4739-AA93-DD7578157AE8 Q31117154-9255269B-A185-4A8B-B18D-63CDAB15B9F7 Q33701891-7392E267-C0D1-4D54-B181-B030013F318D Q33813547-5405978A-F428-4BB0-B56B-E80DBD8E6E61 Q33837238-AB5F0878-665D-42CB-A53D-B3CCB34DF1C3 Q33840627-DF2D6FA3-2705-4EC9-988D-DE8F7A66872B Q33956936-26000723-BD40-44DE-A383-189FC0D8E884 Q33956959-61E4922C-4458-4764-B0C3-D5EA880B1441 Q34076650-11CF0859-7F8B-4886-A004-4F4A9E6A7F9C Q34582710-1B467777-9B12-4BD3-A8A2-DC3FF722B560 Q34584417-24D3962E-72CA-4138-B978-402B7EE1B794 Q34654338-94A84B89-923F-4F8D-8161-4A7294A53F7A Q34685307-91BEA758-E2BA-4D84-A1F4-C31B83F506D6 Q34720833-78A4C83B-E3F6-4693-9D9F-C61F9D65CBAA Q34989407-2D399672-3213-45F4-9C0E-A94C43FF8803 Q35052617-5FB6AD73-8FE2-4F59-8A71-2FA8E53F50BB Q35102866-A0CA3F3F-03C1-4D5C-9F55-2986040B9A26 Q35129909-69CB63EB-73CE-418E-A865-A63A3507B070 Q35591375-9FBE4B92-2F1D-4889-B033-192367F05674 Q35632864-262A7231-9B88-4821-9819-3EBE5A9B682E Q35770976-D0A23446-80A5-4BD1-985D-57F4E1D5835F Q35783279-029C2943-C3D7-4CEF-80EA-1E36E60DC48E Q36043045-89E3F9F0-D88A-4641-B63C-42464EBC971C Q36401411-6C530FE2-1230-43FD-B509-BBF0F93A4F93 Q36444101-AD64F1D9-966C-4862-9588-90B1F3FD07F6 Q36460613-194E05CF-8CE8-4324-821E-40F5ECA8E3C7 Q36648798-5F4E89A2-B473-4CEB-8798-606BDE6449A5 Q36762826-BE9863E9-1791-4E81-A52E-56026E283B5D Q36903648-44A7445F-A09F-4D3F-8BE7-24BE6DE2A936 Q36964084-F47528D2-B1D9-4091-B0E6-7118179F590C Q37448888-F6E4BB44-83D4-4425-816F-C9ED2C29475A Q37618797-230916FC-E562-45E4-B4C5-E1907AD488F5 Q37686246-031A480B-38CD-4C6C-8111-84791FC9FFCB Q37736127-C3583157-A5CD-463B-86BE-C0DB1D20A2A6 Q37790615-2A0A2830-0200-46D4-9232-58CD788E378C

P2860

Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up.

http://www.wikidata.org/entity/Q42653222

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up.

@en

Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up.

@nl

type

label

Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up.

@en

Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up.

@nl

prefLabel

Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up.

@en

Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up.

@nl

P1433

Q42653222-6517EDB8-6E0B-4B37-954C-D9A28F4C30F8

P1476

Q42653222-E0D94050-01C5-4175-9B36-9B181EEA3933

P2093

Q42653222-06D80179-6AF8-458A-BAE3-9C983A48EFF5

Q42653222-2AA3C1FB-FAD5-4784-B446-04E57714F5B1

Q42653222-4838FCBE-A485-4040-96D5-53BB6FA762AD

Q42653222-6D0C35F4-B99F-49F3-9AFF-6FD0B9897FED

Q42653222-98CF48FC-4BDA-4C3B-84AD-2358299D190A

Q42653222-B5BD9E52-488B-44ED-B339-A819EDAF40A4

Q42653222-DA28CA1D-A382-4A8A-9029-2E585284FAE4

Q42653222-E6A647F8-30EE-4A0F-B92D-3FB25641AA90

Q42653222-FD84752B-4F3E-4773-9064-8DC1B1A42677

P304

Q42653222-9744A25E-A3D8-4ECA-B73E-D3E97C1D0E87

P31

Q42653222-784ED22F-5ADA-4FA8-936A-D74B8F87F1BD

P356

Q42653222-592FCAD3-38D3-419B-A6EB-59C0BDB7DBB1

P433

Q42653222-989E997C-98E5-4020-A4E9-3F929FF6D27F

P478

Q42653222-54A95547-937E-4B4F-91D6-D2776E5CB27B

P50

Q42653222-07F25491-E276-4435-8385-EE242441F73B

Q42653222-E1758062-31F7-43F1-842A-44917A3E8403

P577

Q42653222-CCFCC7BC-721B-4B52-BCE5-233FCDE091B8

P698

Q42653222-6AC672AA-ACF8-42D1-AA42-547EF61B4282

P356

ARCHNEUR.62.4.621

P1433

P1476

Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up.

@en

P2093

Andrew M Blamire

http://www.w3.org/2001/XMLSchema#string

Anthony H V Schapira

http://www.w3.org/2001/XMLSchema#string

Bheeshma Rajagopalan

http://www.w3.org/2001/XMLSchema#string

Christopher Turner

http://www.w3.org/2001/XMLSchema#string

J Mark Cooper

http://www.w3.org/2001/XMLSchema#string

Jane L Bradley

http://www.w3.org/2001/XMLSchema#string

Jenifer G Crilley

http://www.w3.org/2001/XMLSchema#string

Paul E Hart

http://www.w3.org/2001/XMLSchema#string

Peter Styles

http://www.w3.org/2001/XMLSchema#string

P304

621-626

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/ARCHNEUR.62.4.621

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

62

http://www.w3.org/2001/XMLSchema#string

P50

P577

2005-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15824263

http://www.w3.org/2001/XMLSchema#string